Quick Navigation

 
back to top

Oncolytic Viro-Immunotherapy 

Image source: Filley AC., Dey M. Front. Oncol. 23 May 2017)

Image source: Filley AC., Dey M. Front. Oncol. 23 May 2017)

 

Oncorus’s armed oHSV selectively infects and replicates in tumor cells, eventually causing tumor cell lysis. Upon lysis, multiple “personalized” tumor antigens and therapeutic immune modulatory payloads are released into the local environment. Neoantigens and immune payloads stimulate and recruit immune cells to destroy local and distant tumors, resulting in a highly effective cancer therapeutic treatment.

 
back to top

Platform

Oncorus is developing potent oncolytic immunotherapies for malignant and benign tumors.

 

Robust Viral Potency

Virulence

Critical γ34.5 gene retained to maintain wild type replication & inhibit IDO activity

Potency

Proprietary glycoprotein modifications to enhance target cell entry.

 

Superior Efficacy

Multiple Immune-Modulatory Payloads

Large 25kb capacity enables integration of multiple payloads capable of recruiting all arms of the immune system.

Tumor Matrix Modification

Matrix metalloproteinases degrade the extracellular matrix and facilitate viral spread, enhancing efficacy.

 

Superior Safety

miR Controlled Replication & Payload Expression

Engineering of miR-T cassettes into critical replication genes allows robust replication in tumor tissues; arming genes expressed in tumor only, increasing potency & limiting toxicity.

Targeted Viral Entry

Retargeted glycoproteins enables selective uptake by cells expressing tumor antigens.

 
back to top

Pipeline

Screen Shot 2017-09-03 at 4.43.05 PM.png
 
 
back to top

Armed oHSV Vector

Injected Tumor

  • Robust anti-tumor effect following direct injection of unarmed Oncorus oHSV

  • Even greater tumor regression with armed Oncorus oHSV

 

Contralateral Tumor

  • Modest abscopal response observed with unarmed oHSV

  • Robust abscopal effect observed in non-injected tumor with single immune payload


A20 flank tumor model demonstrates that armed oHSV induces robust oncolysis in injected tumor (top panel) and potent abscopal response in uninjected tumor (lower panel).